⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21827626 | 1.00 | — | — | |
| SCHEMBL20494381 | 1.00 | — | — | |
| SCHEMBL1144298 | 0.80 | — | — | |
| SCHEMBL64478 | 0.78 | — | — | |
| SCHEMBL1299498 | 0.78 | — | — | |
| SCHEMBL1861623 | 0.78 | — | — | |
| SCHEMBL2105780 | 0.76 | — | — | |
| SCHEMBL3241699 | 0.76 | — | — | |
| SCHEMBL5231042 | 0.76 | — | — | |
| SCHEMBL1863181 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399209-A1 | NEW QUINOLINE DERIVATIVES | Elanco Animal Health GmbH (DE) | 2024-07-17 | — | — | EP | claimed |
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | claimed |
| CN-117957223-A | Quinoline derivatives | 礼蓝动物保健有限公司 | 2024-04-30 | — | — | CN | claimed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | claimed |
| WO-2023036821-A1 | NEW QUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-03-16 | — | — | WO | claimed |
| EP-4148052-A1 | NEW QUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | claimed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| CN-104961666-B | 2-mercaptoacetamide pleuromutilin derivatives, and preparation method and medical application thereof | 南通大学 | 2017-04-12 | — | — | CN | claimed |
| CN-104447450-B | Cysteine amide-type pleuromutilin derivative and preparation method and medical usage | 南通大学 | 2016-09-28 | — | — | CN | claimed |
| US-9388141-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | claimed |
| CN-105339357-A | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE DEUTSCHLAND | 2016-02-17 | — | — | CN | claimed |
| EP-2970146-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| CN-104961666-A | 2-mercaptoacetamide pleuromutilin derivatives, and preparation method and medical application thereof | UNIV NANTONG | 2015-10-07 | — | — | CN | claimed |
| CN-104447450-A | Cysteine amide type pleuromutilin derivative as well as preparation method and medical application thereof | UNIV NANTONG | 2015-03-25 | — | — | CN | claimed |
| US-20140303176-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | claimed |
| WO-2014140246-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | claimed |
| US-20140275104-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | claimed |